Abnormal Savda Munzi improves memory function in a APP/SP1 model of Alzheimer’s disease by improvement of histology, ultrastructure and cholinergic system

International Congress on Neuroimmunology and Therapeutics

DoubleTree by Hilton Hotel San Francisco Airport, San Francisco, CA, USA

Palidan Wushuer and Nurmuhammat Amat

Posters-Accepted Abstracts: J Neurol Disord

Abstract :

Alzheimerâ??s disease (AD) is a debilitating neurodegenerative disorder characterized by increased b-amyloid (Ab) deposition and neuronal dysfunction leading to impaired learning and recall. Abnormal Savda Munziq (ASMq), a formulation has been used traditionally in Uighur medicine system of medicine as a memory enhancer and anti-stressagent. The present study was carried out to evaluate the ameliorating memory impairment in the transgenic mice and to explore the underlying molecular mechanism. Mice brain sections were detected by HE and transmission electron microscopy. Acetylcholine (Ach) levels, acetylcholineesterase (AchE) activity, Choline acetyltransferase (ChAT) activity were assessed in the hippocampus. ASMq treatment for 3 month decreased escape latency and swimming distance of mice from the third day in maze tests, and increased percent time in the target quadrant, along with increased Ach conceteration and improved histology and ultrastructure. The present study suggests that ASMq confers a therapeutic potential to ameliorate AD-like pathology in the brain of AD mice though both regulate histology, ultrastructure and cholinergic system.